Abbott Laboratories (ABT) Delnica Cena
Abbott Laboratories Cena
V zadnjih 19 letih so prihodki Abbott Laboratories rasli 3,6 % letno in dosegli 44,33 Mrd. USD. Dobiček na delnico je rasel 6,6 % letno v zadnjih 19 letih. Za Abbott Laboratories je čista marža 14,7 % padla v primerjavi s 16,4 % pred nekaj leti. Po današnji ceni je dividendna donosnost približno 2,30 %. Izplačilni delež je okoli 63 % dobička. Dividenda je rasla 3,8 % letno v zadnjih 19 letih. Konsenzna 12-mesečna ciljna cena za Abbott Laboratories je 121,00 USD, približno nad tečaj za 18,1 %. Od 32 analitikov jih 26 priporoča nakup — skupni konsenz je Nakup.
Cena delnice Abbott Laboratories
Do teh podatkov prek Eulerpool API
100.000 zahtevkov/mes. brezplačno · brez kartice
Abbott Laboratories poslovni model in analiza delnice
Pogosto postavljena vprašanja o delnici Abbott Laboratories
Abbott Laboratories is a renowned healthcare company with a strong business model focused on providing a diverse range of medical products, diagnostics, nutritional supplements, and pharmaceuticals. By combining technological advancements with innovative research, Abbott aims to enhance the quality of life for individuals worldwide. With a comprehensive portfolio spanning diverse healthcare sectors, including diagnostics, nutrition, diabetes care, medical devices, and branded generic pharmaceuticals, Abbott Laboratories strives to improve patient outcomes and deliver sustainable growth. Through its commitment to scientific excellence and dedication to meeting evolving healthcare needs, Abbott Laboratories has established itself as a trusted leader in the global healthcare industry.
Abbott Laboratories is primarily active in the healthcare industry.
The main competitors of Abbott Laboratories in the market are Johnson & Johnson, Pfizer, and Roche Holding AG.
Abbott Laboratories is a renowned American healthcare company, known for providing a diverse range of medical, pharmaceutical, and nutritional products. Founded in 1888 by Dr. Wallace C. Abbott, the company initially focused on producing pharmaceuticals, including the widely successful alkaloid-based pain reliever, Abbott's ABC Liniment. Over the years, Abbott Laboratories has expanded its portfolio, venturing into areas such as diagnostics, medical devices, and nutrition. The company's commitment to innovation is evident through breakthroughs like the development of the first HIV blood-screening test. Today, Abbott Laboratories continues to play a crucial role in improving health outcomes worldwide, with its cutting-edge technology and a focus on delivering quality healthcare solutions.
Abbott Laboratories has achieved several significant milestones throughout its history. One major milestone was the development and commercialization of the first-ever HIV blood screening test, which greatly contributed to safer transfusions and the prevention of the spread of HIV. Additionally, Abbott Laboratories introduced breakthrough medical devices, such as the FreeStyle® Libre system, a continuous glucose monitoring system for diabetes management. The company also played a crucial role in the fight against COVID-19 by developing rapid diagnostic tests for the virus. Furthermore, Abbott Laboratories has consistently been recognized for its commitment to innovation and sustainability, making it a leading healthcare company globally.
Abbott Laboratories is primarily present in multiple countries and regions worldwide. The company operates in more than 160 countries, including the United States, Canada, Europe, Asia-Pacific, Latin America, and the Middle East. With a strong global footprint, Abbott Laboratories has established itself as a leading healthcare company in various markets, delivering innovative medical products, diagnostics, nutritionals, and pharmaceuticals to improve people's health and well-being.
Abbott Laboratories is committed to its core values of putting patients first, serving customers with innovative solutions, and operating with integrity in all aspects of its business. The company's corporate philosophy centers around improving life through the development of groundbreaking technologies and products. Abbott Laboratories prides itself on its dedication to delivering reliable healthcare solutions, fostering collaboration with healthcare professionals, and investing in research and development to address unmet medical needs. With a focus on providing high-quality and accessible healthcare options, Abbott Laboratories strives to create positive impacts in communities worldwide through its diverse portfolio of medical devices, diagnostics, nutrition, and pharmaceutical products.
Analitiki trenutno določajo povprečno ciljno ceno 123,64 USD za delnico Abbott Laboratories (mediana: 121,00 USD), kar pomeni +20,7 % glede na zadnjo ceno. Konsenz temelji na 32 ocenah.
32 analitikov trenutno ocenjuje delnico Abbott Laboratories: 26 priporoča nakup, 6 držanje in 0 prodajo. Za 2026 analitiki pričakujejo, da bo Abbott Laboratories ustvaril prihodke 50,30 Mrd. USD in dobiček na delnico 5,52 USD.
Po trenutnem tečaju se delnica Abbott Laboratories trguje po 91,44 EUR (102,42 USD).
Delnica Abbott Laboratories (ABT) je uvrščena na 9 borzah, med njimi: NYSE (ABT), London (0Q15.L), SIX (Zürich) (ABT.SW), XETRA (ABL.DE), Frankfurt (ABL.F), München (ABL.MU), Düsseldorf (ABL.DU), Hamburg (ABL.HM).
Abbott Laboratories is a global company specializing in the development, manufacturing, and marketing of health products and services. Its business model is divided into different divisions that focus on the needs of patients, doctors, and healthcare systems. The divisions of Abbott Laboratories include Diagnostics, Medical Devices, Nutrition, and Pharmaceutical. The company aims to continuously develop innovative technologies and products to improve healthcare, and it offers a wide range of services and support programs for patients. Abbott Laboratories has established a strong market position and global presence in over 160 countries since its establishment in 1888. It also pursues a successful acquisition strategy to expand its product portfolio, such as the acquisition of St. Jude Medical in 2017 to enhance its cardiovascular products and services. Overall, Abbott Laboratories aims to improve healthcare and meet the needs of patients, doctors, and healthcare systems through its comprehensive strategy focused on developing innovative products, expanding into new markets, and increasing efficiency.
pričakovane prihodki za Abbott Laboratories znašajo 50,30 Mrd. USD. Ta vrednost temelji na trenutnih finančnih podatkih in odraža poslovno uspešnost podjetja.
pričakovane dobiček za Abbott Laboratories znaša 9,64 Mrd. USD. Čisti dobiček odraža donosnost podjetja po odbitku vseh stroškov.
Razmerje cena-dobiček (P/E) Abbott Laboratories je trenutno 18,55. Razmerje P/E primerja trenutno ceno delnice z dobičkom na delnico in pomoči vlagateljem oceniti vrednost delnice Abbott Laboratories.
Razmerje cena-prihodki (P/S) Abbott Laboratories je trenutno 3,56. Razmerje P/S primerja tržno vrednost s celotnimi letnimi prihodki in služi kot kazalnik vrednotenja delnice Abbott Laboratories.
Eulerpool ocena kvalitete za Abbott Laboratories je 6/10.
ISIN Abbott Laboratories je US0028241000. ISIN (International Securities Identification Number) je svetovni edinstven identifikator za vrednostne papirje.
WKN Abbott Laboratories je 850103. WKN (Wertpapierkennnummer) je šestmestna nemška oznaka za identifikacijo vrednostnih papirjev.
Ticker Abbott Laboratories je ABT. Ticker simbol se uporablja za trgovanje z delnicami Abbott Laboratories na borzi.
Abbott Laboratories delnica
Abbott Laboratories Konkurenčna skupina
Abbott Laboratories Ticker
Abbott Laboratories FIGI
Vse ključne kazalnike in poglobljeno analizo Abbott Laboratories v detaljnem pregledu
Naša analiza delnic Abbott Laboratories vključuje pomembne finančne kazalnike, kot so prihodki, dobiček, razmerje cena/dobiček (P/E), razmerje cena/prihodki (P/S), EBIT ter informacije o dividendah. Prav tako preučujemo aspekte, kot so delnice, tržna kapitalizacija, dolgovi, lastniški kapital in obveznosti Abbott Laboratories. Če iščete podrobnejše informacije o teh temah, na naših podstraneh nudimo obsežne analize: